PPM1D and ovarian carcinoma: Amplification of the genomic locus 17q23 coding for PPM1D or production of a highly stable and enzymatically active mutant of PPM1D have been reported in breast and ovarian cancer, therapy‐induced acute myeloid leukaemia (t‐AML) and other haematological malignancies [28, 29, 30, 31].